1 / 51

Peripheral T-Cell Lymphoma in 2013

Peripheral T-Cell Lymphoma in 2013. Program Goal. WHO 2008 Classification of Mature T/NK-Cell Neoplasms. Use of the Term PTCL. PTCL, PTCL Mature (Post-Thymic) T-Cell Lymphomas. International PTCL Study: Major NHL Types by Region.

gari
Download Presentation

Peripheral T-Cell Lymphoma in 2013

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Peripheral T-Cell Lymphoma in 2013

  2. Program Goal

  3. WHO 2008 Classification of Mature T/NK-Cell Neoplasms

  4. Use of the Term PTCL

  5. PTCL, PTCL Mature (Post-Thymic) T-Cell Lymphomas

  6. International PTCL Study: Major NHL Types by Region

  7. Key Points in the Pathology Characteristics of the Most Common Subtypes of PTCL

  8. ALK and ALCL

  9. Outcomes by PTCL Subtypes

  10. Prognostic Indices for PTCL

  11. Autologous Stem Cell Transplantation as First-line Therapy in PTCL: Results of a Prospective Multicenter Study

  12. CHOP: First-line Treatment of PTCL

  13. Alemtuzumab (A) + ChemotherapyFirst-line treatment of PTCL

  14. CHOP+ and Non-CHOP: First-line Treatment of PTCL

  15. Treatment and Prognosis of Mature T-Cell and NK-Cell Lymphoma: Event-Free Survival of Younger Patients

  16. Treatment and Prognosis of Mature T-Cell and NK-Cell Lymphoma: Event-free Survival of Younger Patients (cont)

  17. Autologous Stem Cell Transplantation as First-line Therapy in PTCL: Survival

  18. Prognostic Factors in Trials of ASCT in First Remission

  19. ICE and Planned ASCT for Relapsed/Refractory T-Cell Lymphoma: PFS From ICE

  20. CIBMTR Auto and Allo for PTCL: Outcomes Excluding Patients in CR1

  21. Retrospective Analyses of Allogeneic Stem-Cell Transplantation for PTCL

  22. Approved Agents in Relapsed/Refractory PTCL

  23. PROPEL: Adverse Events ≥ Gr 3 Occurring in ≥ 3% of Patients (n = 111)

  24. Treatment-related Adverse Events With Romidepsin in ≥ 20% of Patients (N = 131)

  25. Brentuximab Vedotin: Phase 2 Study in Relapsed/Refractory Systemic ALCL

  26. Brentuximab Vedotin in Relapsed ALCL: Toxicities

  27. Brentuximab: Best Clinical Response by Disease Diagnosis

  28. Brentuximab: Maximum Tumor Volume Reduction by Frequency of CD30+ Cells

  29. Front-line Therapy: Study Design (Combination Therapy Arms)

  30. Front-line Therapy: Best Response by Disease Diagnosis

  31. Bendamustine in T-Cell Lymphoma (BENTLY Trial)

  32. Lenalidomide in Relapsed/Refractory TCL: Phase 2 Trial

  33. Belinostat: PTCL Response Assessed by Central Review

  34. Belinostat: Response Rate by CPRG Lymphoma Diagnosis

  35. Belinostat: Grade ≥3 Nonhematologic AEs in Patients With R/R PTCL (N=120)

  36. MLN8237: Response (PR + CR) by Histology

  37. IPI-145: A PI3K-δ,γ Inhibitor

  38. Early Signs of Clinical Activity of IPI-145 in T-Cell Lymphoma

  39. Mogamulizumab (KW-0761)Anti-CCR4 Monoclonal Antibody

  40. Recommended Approach to Patients With Relapsed PTCL (NOS, AITL, ALCL)

  41. Abbreviations

  42. Abbreviations (cont)

  43. Abbreviations (cont)

  44. Abbreviations (cont)

  45. References

  46. References (cont)

  47. References (cont)

  48. References (cont)

  49. References (cont)

  50. References (cont)

More Related